FDA Brief

Warning letters Drugs

FDA warning letter to

7Tabz Retail, LLC

High riskIssued Jun 25, 2025Posted Jul 15, 2025Center for Drug Evaluation and Research (CDER)

FDA says 7Tabz Retail sells unapproved 7-OH drug products online with drug-like claims.

What happened

FDA reviewed www.pop7tabz.com in May 2025, not an inspection. It found product pages and blog/FAQ pages marketing 7-OH products with claims such as pain relief, mood boost, and relaxation, which FDA says make them drugs. FDA also said it has received adverse event reports involving 7-OH products, including the firm's products, and cited safety concerns because 7-OH is a potent opioid-like compound.

What FDA found

  1. The products are unapproved new drugs—meaning FDA has not approved them for sale—because no approved application is in effect.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  2. FDA's website review found claims that the products relieve pain and affect mood, so they are drugs under the law.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  3. FDA says the products are not generally recognized as safe and effective for the claimed uses, so they are 'new drugs.'

    FD&C Act section 201(p), 21 U.S.C. 321(p)
  4. FDA says 7-OH is a new dietary ingredient with inadequate safety information, so dietary supplements containing it are adulterated.

    FD&C Act section 402(f)(1)(B), 21 U.S.C. 342(f)(1)(B)
  5. Selling an adulterated dietary supplement is prohibited.

    FD&C Act section 301(a), 21 U.S.C. 331(a)

What FDA wants

FDA asks the company to notify it in writing within 15 working days of the steps taken to correct the violations, how it will prevent recurrence, and related documentation; if correction cannot be completed in that time, the company must state why and when it will finish.

Who should pay attention

  • retailers selling kratom or 7-OH products online
  • brands and distributors of 7-OH products
  • companies making drug-like claims for supplements

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk